The alkylating agent penclomedine induces degeneration of purkinje cells in the rat cerebellum

Investigational New Drugs

Volumn 21, Issue 3, 2003, Pages 269-279

  O'Reilly, Seamus ^a   O'Hearn, Elizabeth ^a   Struck, Robert F ^c   Rowinsky, Eric K ^b   Molliver, Mark E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CTRC Institute for Drug Development   (United States)

^c SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

Antineoplastic agent; Ataxia; Cerebellum; Neurotoxicity; Penclomedine; Purkinje cell

Indexed keywords

4 O NORPENCLOMEDINE; ALKYLATING AGENT; CALBINDIN; PENCLOMEDINE; PICOLINIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEGENERATION; CELL LOSS; CEREBELLUM; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; FIRST PASS EFFECT; HISTOCHEMISTRY; HISTOLOGY; MALE; METABOLITE; MICROGLIA; NERVE INJURY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PURKINJE CELL; RAT; RAT STRAIN; XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, INTRAPERITONEAL; MALE; NERVE DEGENERATION; PICOLINES; PURKINJE CELLS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0345714783     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1025456224751     Document Type: Article

References (30)

1. Plowman J, Harrison SD, Jr, Dykes DJ, Paull KD, Narayanan V, Tobol HK, Griswold DP, Jr: Preclinical antitumor activity of an alpha picoline derivative, penclomedine (NSC 338720), on human and murine tumors. Cancer Res 49: 1909-1915, 1989
2. Harrison SD, Jr, Plowman J, Dykes DJ, Waud WR and Griswold DP, Jr: Preclinical antitumor activity of penclomedine in mice: cross resistance, schedule dependence, and oral activity against tumor xenografts in brain. Cancer Res 51: 1979-1983, 1991
3. Reid JM, Mathieson DA, Benson LM, Kuffel MJ, Ames MM: Murine pharmacokinetics and metabolism of penclomedine [3,5-dichloro-2,4-dimethoxy-6-(trichloromethyl) pyridine, NSC 338720]. Cancer Res 52: 2830-2834, 1992
4. Hartman NR, O'Reilly S, Rowinsky EK, Collins J, Strong JM: Murine and human in vivo penclomedine metabolism. Clin Cancer Res 2: 953-962, 1996
5. 14C-penclomedine in rats. Clin Cancer Res 2: 541-548, 1996
6. O'Reilly, S: Pharmacologic Studies of Penclomedine. Doctoral dissertation. Johns Hopkins University/Johns Hopkins University Press, Baltimore, MD, 1996
7. Waud WR, Tiwari A, Schmid SM, Shih TW, Strong JM, Hartman NR, O'Reilly S, Struck RF: 4-Demethylpenclomedine, an antitumor active, non-neurotoxic metabolite of penclomedine. Cancer Res 57: 815-817, 1997
8. Freidman H, Keir S, Bigner D, Struck, R: Treatment of CNS tumor xenografts with penclomedine and 4-demethylpenclomedine. Proc Amer Assoc Cancer Res 39: 218, 1998 (Abstract)
9. Division of Cancer Treatment, Diagnosis and Centers, National Cancer Institute: Penclomedine Investigators Brochure. National Cancer Institute, Bethesda, MD, 1992
10. O'Reilly S, Grochow LB, Donehower RC, Bowling K, Chen TL, Hartman N, Struck RF, Rowinsky EK: Phase I and pharmacologic study of penclomedine, a novel alkylating agent, in patients with solid tumors. J Clin Oncol 15: 1974-1984, 1997
11. Berlin J, Stewart JA, Storer B, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Simon K, Wilding, G: Phase I clinical and pharmacokinetic trial of penclomedine using a novel, two-stage trial design for patients with advanced malignancy. J Clin Oncol 16: 1142-1149, 1998
12. Jodrell DI, Bowman A, Stewart M, Dunlop N, French R, MacLellan A, Cummings J, Smyth JF: Dose-limiting neurotoxicity in a phase I study of penclomedine (NSC 388720, CRC 88-04), a synthetic alpha-picoline derivative, administered intravenously. Br J Cancer 77: 808-811, 1998
13. Kreutzberg GW: Microglia: a sensor for pathological events in the CNS. Trends Neurosci 19: 312-318, 1996
14. Thomas WE: Brain macrophages: evaluation of microglia and their functions. Brain Res Rev 17: 61-74, 1992
15. 28K protein and mRNA localization in the rat brain. Eur J Neurosci 2: 1118-1126, 1990
16. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE: Quantitative comparison of toxicity of anti-cancer agents in mouse, rat, dog, monkey and man. Cancer Chemother Rep 50: 219-244, 1966
17. O'Hearn E, Long DB, Molliver ME: Ibogaine induces glial activation in parasagittal zones in the cerebellum. Neuro-Report 4: 299-302, 1993
18. Mamounas LA, Mullen CA, O'Hearn E, Molliver ME: Dual serotonergic projections to forebrain in the rat: morphologically distinct 5-HT axon terminals exhibit differential vulnerability to neurotoxic amphetamine derivatives. J Comp Neurol 314: 435-440, 1991
19. O'Hearn E, Molliver ME: Degeneration of Purkinje cells in parasagittal zones in the cerebellar vermis after treatment with ibogaine or harmaline. Neuroscience 55: 303-310, 1993
20. Näkki R, Koistinaho J, Sharp FR, Sagar SM: Cerebellar toxicity of phencyclidine. J Neurosci 15: 2097-2108, 1995
21. Llinás R, Yarom Y: Oscillatory properties of guinea-pig inferior olivary neurons and their pharmacological modulation: an in vitro study. J Physiol 376: 163-182, 1986
22. O'Hearn E, Molliver ME: The olivocerebellar projection mediates ibogaine-induced degeneration of Purkinje cells: a model of indirect, trans-synaptic excitotoxicity. J Neurosci 17: 8828-8841, 1997
23. O'Hearn E, Molliver ME: Neurotoxins and neuronal death: an animal model of excitotoxicity. In: Koliatsos VE, Ratan RR (eds) Cell Death and Diseases of the Nervous System. Human Press Inc., Totowa, NJ, 1999, pp 221-245
24. Nicotera P, Bellomo G, Orrenius S: Calcium-mediated mechanisms in chemically induced cell death. Annu Rev Pharmacol Toxicol 32: 449-470, 1992
25. Siman R, Noszek JC: Excitatory amino acids activate calpain I and induce structural protein breakdown in vivo. Neuron 1: 279-287, 1988
26. Llinás R, Sasaki K: The functional organization of the olivocerebellar system as examined by multiple Purkinje cell recordings. Eur J Neurosci 1: 587-602, 1989
27. Llinás R, Nicholson C: Reversal properties of climbing fiber potential in cat Purkinje cells: an example of a distributed synapse. J Neurophysiol 39: 311-323, 1976
28. Winkelman MD, Hines JD: Cerebellar degeneration caused by high dose cytosine arabinoside: a clinicopathologic study. Ann Neurol 14: 520-527, 1983
29. Wetts R, Moran T, Oster-Granite M, Gearhart J: Effect of Purkinje cell loss on complex motor behavior. Soc Neurosci 11: 1037, 1985 (Abstract)
30. O'Reilly S, Strong J, Bowling K, Rowinsky EK, Donehower RC, Collins J, Hartman NR: A pharmacologic study of the oral bioavailability study of oral penclomedine. Cancer Chemother Pharmacol 48: 223-228, 2001